Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis

BACKGROUND: KRAS mutation status in codons 12 and 13 is recognized as a predictive factor for resistance to anti-EGFR monoclonal antibodies. Despite having a wild type KRAS (wt-KRAS), not all patients with wt-KRAS respond to anti-EGFR antibody treatment. Additional mechanisms of resistance may activ...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Versita, Warsaw 2011
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3423757/
https://ncbi.nlm.nih.gov/pubmed/22933967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/v10019-011-0039-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller